is tirzepatide the same as zepbound vs Zepbound® (Tirzepatide) Prescribed Online with

Concern was initially raised by the findings of the SUSTAIN-6 CVOT that suggested the risk of DR complications was elevated in patients using semaglutide compared with placebo (3.0% vs 1.8%, P = .02)

Semaglutide produced roughly 15% average body-weight loss in the STEP trials over 68 weeks (Wilding et al., N Engl J Med, 2021)

However, the majority of patients in this study were concomitantly administered metformin, and the dosage of semaglutide employed was higher (on average 0.7 mg/week subcutaneously) than that employed in this study (7 mg per day orally, corresponding to a weekly dose of 0.25 mg subcutaneously)

For the first time, a pharmacological obesity treatment, semaglutide, has been shown to reduce major adverse cardiovascular events in people with obesity and established cardiovascular disease and there are ongoing cardiovascular outcome trials with other incretin therapies

The descriptions of potential benefits are not guarantees and are not a substitute for an individualized medical evaluation